Summarized by Masters of Longevity from Longevity Technology.
A biotech hiring a drug-approval veteran to pivot from an extensive mammalian longevity screen toward clinical translation and partner-ready development.
Key Takeaways
- Longevica completed a four-year, $13 million full-lifespan mammalian screen at The Jackson Laboratory across over 1,000 small molecules.
- Dr Prasun Mishra, with prior roles at Genentech, Roche, NIH, and a track record of 12 clinical programs and four regulatory approvals, was named CEO.
- The company is advancing lead candidates toward IND-enabling preclinical studies while pursuing ML-driven target discovery and veterinary pathways for faster validation.
